

- COMPLETED
- CURRENTLY
- PENDING

Health Technology Assessment (HTA)

The systematic evaluation of properties, effects, and/or impacts of the health technology. It is a multidisciplinary process to evaluate the social, economic, organizational and ethical issues of a health intervention or health technology and used to inform policy decisions
They make a recommendation that will guide provincial plans on whether they should reimburse the drug or not.
 Uses QALY* as a unit of measure

pan-Canadian Pharmaceutical Alliance (pCPA)
 negotiates on behalf of the provincial, territorial and federal programs the price that will actually be paid.

PLA: a negotiated agreement between each province and drug manufacturer for public reimbursement

Trikafta
 Vertex Pharmaceuticals

Drug is submitted for review by Health Canada

Health Canada

The drug is reviewed to assess its safety, efficacy and quality data. A decision is made based on the potential benefits and risks
 Issues notice of compliance (NOC)
 Vertex has been granted a priority review

PMPRB
 Patented
 Medicine Pricing
 Review Board

PMPRB: a federal, independent, quasi-judicial agency that ensures that the prices of patented medicines sold in Canada are not excessive. Reports to the Federal Health Minister

**Health Technology Assessment
 CADTH/INESSS**

Public Drug Plans
pCPA

Private Drug Plans

Private Insurance Reimbursement
 Industry frequently aligns their coverage with HTA recommendations/assessments

Product Listing Agreement
PLA

Patient Access

***QALY:** Quality-Adjusted Life Year
 a generic measure of disease burden, including both the quality and the quantity of life lived. It is used in economic evaluation to assess the value of medical interventions. One QALY equates to one year in perfect health.